BSX Reports Strong Q3 2025 Adjusted EPS Amidst Robust Revenue Growth

Boston Scientific (BSX.US) announced strong financial results for the third quarter of 2025, with net sales reaching $5.065 billion. This represents a significant 20.3% increase on a reported basis compared to the prior year period. The company also achieved adjusted EPS of $0.75 per share, surpassing analyst estimates of $0.71 and the company's own guidance range of $0.70 to $0.72.

Robust Sales Across Segments and Regions

The company demonstrated strong performance across its business segments, with Cardiovascular net sales increasing by 22.4% on a reported basis year-over-year. MedSurg also saw healthy growth, reporting a 16.4% increase in net sales compared to the prior year period. Geographically, the United States led with a 27.0% reported and operational net sales increase.

Operational net sales growth, which excludes the impact of foreign currency fluctuations, reached 19.4%, while organic net sales grew by 15.3%. This organic growth exceeded the company's guidance range of 12% to 14%. The company's Emerging Markets also contributed positively with an 11.8% reported net sales growth.

Strategic Developments and Product Innovation

Boston Scientific advanced its product portfolio and market presence through key strategic developments in Q3 2025. Notably, the company received PMDA approval in Japan for expanded labeling of its FARAPULSE™ Pulsed Field Ablation System for treating persistent atrial fibrillation. Additionally, the company commenced enrollment in the AGENT DCB STANCE trial to evaluate the AGENT™ Drug-Coated Balloon for coronary lesions.

The company also expanded its neuromodulation capabilities by announcing an agreement to acquire Nalu Medical, Inc., a developer of peripheral nerve stimulation technology for chronic pain. This follows the publication of positive five-year outcomes from the INTREPID study, demonstrating sustained benefits of deep brain stimulation for Parkinson's disease. Furthermore, an asset acquisition with Elutia, Inc. was completed, bringing the EluPro™ BioEnvelope and CanGaroo® Envelope into Boston Scientific's offerings.

Positive Full Year and Q4 2025 Outlook

Looking ahead, Boston Scientific projects continued strong performance, with full-year 2025 net sales growth estimated at approximately 20% on a reported basis and 15.5% organically. The company forecasts full-year adjusted EPS to be in the range of $3.02 to $3.04.

For the fourth quarter of 2025, net sales growth is anticipated to be between 14.5% and 16.5% on a reported basis, and 11% to 13% organically. Adjusted EPS for Q4 2025 is estimated to be between $0.77 and $0.79 per share, signaling ongoing confidence in its operational strategy and market position.